Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 337-353 , September 2006

Cortisol metabolism in hypertension

  • Paul M. Stewart, MD, FRCP, FMedSci (Professor of Medicine)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44 121 415 8708; Fax: +44 121 415 8712.

References 

  1. Ferriss JB, Beevers DG, Brown JJ, et al. Low-renin (“primary”) hyperaldosteronism. Differential diagnosis and distinction of sub-groups within the syndrome. American Heart Journal. 1978;95:641–658
  2. Stowasser M, Gordon RD. Primary aldosteronism. Best Practice & Research. Clinical Endocrinology and Metabolism. 2003;17:591–605
  3. Tomlinson JW, Walker EA, Bujalska IJ, et al. 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response. Endocrine Reviews. 2004;25:831–866
  4. Draper N, Stewart PM. 11beta-hydroxysteroid dehydrogenase and the pre-receptor regulation of corticosteroid hormone action. The Journal of Endocrinology. 2005;186:251–271
  5. Ricketts ML, Verhaeg JM, Bujalska I, et al. Immunohistochemical localization of type 1 11beta-hydroxysteroid dehydrogenase in human tissues. The Journal of Clinical Endocrinology and Metabolism. 1998;83:1325–1335
  6. Ozols J. Lumenal orientation and post-translational modifications of the liver microsomal 11 beta-hydroxysteroid dehydrogenase. The Journal of Biological Chemistry. 1995;270:2305–2312
  7. Lavery GG, Walker EA, Draper N, et al. Hexose-6-phosphate dehydrogenase Knock-out mice lack 11beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation. The Journal of Biological Chemistry. 2006;281:6546–6551
  8. Stewart PM, Murry BA, Mason JI. Human kidney 11 beta-hydroxysteroid dehydrogenase is a high affinity nicotinamide adenine dinucleotide-dependent enzyme and differs from the cloned type I isoform. The Journal of Clinical Endocrinology and Metabolism. 1994;79:480–484
  9. Shams M, Kilby MD, Somerset DA, et al. 11Beta-hydroxysteroid dehydrogenase type 2 in human pregnancy and reduced expression in intrauterine growth restriction. Human Reproduction (Oxford, England). 1998;13:799–804
  10. Funder JW, Pearce PT, Smith R, et al. Mineralocorticoid action: target tissue specificity is enzyme, not receptor, mediated. Science. 1988;242:583–585
  11. Wilson RC, Nimkarn S, New MI. Apparent mineralocorticoid excess. Trends in Endocrinology and Metabolism. 2001;12:104–111
  12. White PC, Mune T, Agarwal AK. 11 Beta-hydroxysteroid dehydrogenase and the syndrome of apparent mineralocorticoid excess. Endocrine Reviews. 1997;18:135–156
  13. Dave-Sharma S, Wilson RC, Harbison MD, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. The Journal of Clinical Endocrinology and Metabolism. 1998;83:2244–2254
  14. Ulick S, Levine LS, Gunczler P, et al. A syndrome of apparent mineralocorticoid excess associated with defects in the peripheral metabolism of cortisol. The Journal of Clinical Endocrinology and Metabolism. 1979;49:757–764
  15. Shackleton CH, Rodriguez J, Arteaga E, et al. Congenital 11 beta-hydroxysteroid dehydrogenase deficiency associated with juvenile hypertension: corticosteroid metabolite profiles of four patients and their families. Clinical Endocrinology (Oxford). 1985;22:701–712
  16. Monder C, Shackleton CH, Bradlow HL, et al. The syndrome of apparent mineralocorticoid excess: its association with 11 beta-dehydrogenase and 5 beta-reductase deficiency and some consequences for corticosteroid metabolism. The Journal of Clinical Endocrinology and Metabolism. 1986;63:550–557
  17. Stewart PM, Corrie JE, Shackleton CH, et al. Syndrome of apparent mineralocorticoid excess. A defect in the cortisol-cortisone shuttle. The Journal of Clinical Investigation. 1988;82:340–349
  18. Wilson RC, Dave-Sharma S, Wei JQ, et al. A genetic defect resulting in mild low-renin hypertension. Proceedings of the National Academy of Sciences of the U S A. 1998;95:10200–10205
  19. Ulick S, Tedde R, Mantero F. Pathogenesis of the type 2 variant of the syndrome of apparent mineralocorticoid excess. The Journal of Clinical Endocrinology and Metabolism. 1990;70:200–206
  20. Mantero F, Palermo M, Petrelli MD, et al. Apparent mineralocorticoid excess: type I and type II. Steroids. 1996;61:193–196
  21. Palermo M, Cossu M, Shackleton CH. Cure of apparent mineralocorticoid excess by kidney transplantation. The New England Journal of Medicine. 1998;339:1787–1788
  22. Albiston AL, Obeyesekere VR, Smith RE, et al. Cloning and tissue distribution of the human 11 beta-hydroxysteroid dehydrogenase type 2 enzyme. Molecular and Cellular Endocrinology. 1994;105:R11–R17
  23. Agarwal AK, Rogerson FM, Mune T, et al. Gene structure and chromosomal localization of the human HSD11K gene encoding the kidney (type 2) isozyme of 11 beta-hydroxysteroid dehydrogenase. Genomics. 1995;29:195–199
  24. Quinkler M, Stewart PM. Hypertension and the cortisol-cortisone shuttle. The Journal of Clinical Endocrinology and Metabolism. 2003;88:2384–2392
  25. Mune T, Rogerson FM, Nikkila H, et al. Human hypertension caused by mutations in the kidney isozyme of 11 beta-hydroxysteroid dehydrogenase. Nature Genetics. 1995;10:394–399
  26. Wilson RC, Harbison MD, Krozowski ZS, et al. Several homozygous mutations in the gene for 11 beta-hydroxysteroid dehydrogenase type 2 in patients with apparent mineralocorticoid excess. The Journal of Clinical Endocrinology and Metabolism. 1995;80:3145–3150
  27. Wilson RC, Krozowski ZS, Li K, et al. A mutation in the HSD11B2 gene in a family with apparent mineralocorticoid excess. The Journal of Clinical Endocrinology and Metabolism. 1995;80:2263–2266
  28. Stewart PM, Krozowski ZS, Gupta A, et al. Hypertension in the syndrome of apparent mineralocorticoid excess due to mutation of the 11 beta-hydroxysteroid dehydrogenase type 2 gene. Lancet. 1996;347:88–91
  29. Kitanaka S, Katsumata N, Tanae A, et al. A new compound heterozygous mutation in the 11 beta-hydroxysteroid dehydrogenase type 2 gene in a case of apparent mineralocorticoid excess. The Journal of Clinical Endocrinology and Metabolism. 1997;82:4054–4058
  30. Lavery GG, Ronconi V, Draper N, et al. Late-onset apparent mineralocorticoid excess caused by novel compound heterozygous mutations in the HSD11B2 gene. Hypertension. 2003;42:123–129
  31. Nunez BS, Rogerson FM, Mune T, et al. Mutants of 11beta-hydroxysteroid dehydrogenase (11-HSD2) with partial activity: improved correlations between genotype and biochemical phenotype in apparent mineralocorticoid excess. Hypertension. 1999;34:638–642
  32. Li A, Li KX, Marui S, et al. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. Journal of Hypertension. 1997;15:1397–1402
  33. Card WI, Mitchell W, Strong JA, et al. Effects of liquorice and its derivatives on salt and water metabolism. Lancet. 1953;1:663–668
  34. Farese RV, Biglieri EG, Shackleton CH, et al. Licorice-induced hypermineralocorticoidism. The New England Journal of Medicine. 1991;325:1223–1227
  35. Conn JW, Rovner DR, Cohen EL. Licorice-induced pseudoaldosteronism. Hypertension, hypokalemia, aldosteronopenia, and suppressed plasma renin activity. The Journal of the American Medical Association. 1968;205:492–496
  36. Stewart PM, Wallace AM, Valentino R, et al. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 1987;2:821–824
  37. Kageyama Y, Suzuki H, Saruta T. Glycyrrhizin induces mineralocorticoid activity through alterations in cortisol metabolism in the human kidney. The Journal of Endocrinology. 1992;135:147–152
  38. Morris DJ, Semafuko WE, Latif SA, et al. Detection of glycyrrhetinic acid-like factors (GALFs) in human urine. Hypertension. 1992;20:356–360
  39. Lo YH, Sheff MF, Latif SA, et al. Kidney 11 beta-HSD2 is inhibited by glycyrrhetinic acid-like factors in human urine. Hypertension. 1997;29:500–505
  40. Walker BR, Aggarwal I, Stewart PM, et al. Endogenous inhibitors of 11 beta-hydroxysteroid dehydrogenase in hypertension. The Journal of Clinical Endocrinology and Metabolism. 1995;80:529–533
  41. Palermo M, Shackleton CH, Mantero F, et al. Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man. Clinical Endocrinology (Oxford). 1996;45:605–611
  42. Beretta-Piccoli C, Davies DL, Brown JJ, et al. Relation of blood pressure with body and plasma electrolytes in Conn's syndrome. Journal of Hypertension. 1983;1:197–205
  43. Walker BR, Stewart PM, Shackleton CH, et al. Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension. Clinical Endocrinology (Oxford). 1993;39:221–227
  44. Soro A, Ingram MC, Tonolo G, et al. Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension. Hypertension. 1995;25:67–70
  45. Walker BR. Steroid metabolism in metabolic syndrome X. Best Practice & Research. Clinical Endocrinology and Metabolism. 2001;15:111–122
  46. Walker BR, Phillips DI, Noon JP, et al. Increased glucocorticoid activity in men with cardiovascular risk factors. Hypertension. 1998;31:891–895
  47. Mariniello B, Ronconi V, Sardu C, et al. Analysis of the 11beta-hydroxysteroid dehydrogenase type 2 gene (HSD11B2) in human essential hypertension. American Journal of Hypertension. 2005;18:1091–1098
  48. Watson B, Bergman SM, Myracle A, et al. Genetic association of 11 beta-hydroxysteroid dehydrogenase type 2 (HSD11B2) flanking microsatellites with essential hypertension in blacks. Hypertension. 1996;28:478–482
  49. Smolenicka Z, Bach E, Schaer A, et al. A new polymorphic restriction site in the human 11 beta-hydroxysteroid dehydrogenase type 2 gene. The Journal of Clinical Endocrinology and Metabolism. 1998;83:1814–1817
  50. Brand E, Kato N, Chatelain N, et al. Structural analysis and evaluation of the 11beta-hydroxysteroid dehydrogenase type 2 (11beta-HSD2) gene in human essential hypertension. Journal of Hypertension. 1998;16:1627–1633
  51. Williams TA, Mulatero P, Filigheddu F, et al. Role of HSD11B2 polymorphisms in essential hypertension and the diuretic response to thiazides. Kidney International. 2005;67:631–637
  52. Lovati E, Ferrari P, Dick B, et al. Molecular basis of human salt sensitivity: the role of the 11beta-hydroxysteroid dehydrogenase type 2. The Journal of Clinical Endocrinology and Metabolism. 1999;84:3745–3749
  53. Agarwal AK, Giacchetti G, Lavery G, et al. CA-Repeat polymorphism in intron 1 of HSD11B2: effects on gene expression and salt sensitivity. Hypertension. 2000;36:187–194
  54. Carvajal CA, Romero DG, Mosso LM, et al. Biochemical and genetic characterization of 11 beta-hydroxysteroid dehydrogenase type 2 in low-renin essential hypertensives. Journal of Hypertension. 2005;23:71–77
  55. White PC, Agarwal AK, Li A, et al. Possible association but no linkage of the HSD11B2 gene encoding the kidney isozyme of 11beta-hydroxysteroid dehydrogenase to hypertension in Black people. Clinical Endocrinology (Oxford). 2001;55:249–252
  56. Kadowitz PJ, Yard AC. Influence of hydrocortisone on cardiovascular responses to epinephrine. European Journal of Pharmacology. 1971;13:281–286
  57. Yard AC, Kadowitz PJ. Studies on the mechanism of hydrocortisone potentiation of vasoconstrictor responses to epinephrine in the anesthetized animal. European Journal of Pharmacology. 1972;20:1–9
  58. Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Critical Care Medicine. 1999;27:723–732
  59. Annane D, Bellissant E, Sebille V, et al. Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. British Journal of Clinical Pharmacology. 1998;46:589–597
  60. Fowler NO, Chou NH. Potentiation of smooth muscle contraction by adrenal steroids. Circulation Research. 1961;9:153–156
  61. Sakaue M, Hoffman BB. Glucocorticoids induce transcription and expression of the alpha 1B adrenergic receptor gene in DTT1 MF-2 smooth muscle cells. The Journal of Clinical Investigation. 1991;88:385–389
  62. Ullian ME, Walsh LG, Morinelli TA. Potentiation of angiotensin II action by corticosteroids in vascular tissue. Cardiovascular Research. 1996;32:266–273
  63. Scott BA, Lawrence B, Nguyen HH, et al. Aldosterone and dexamethasone binding in human arterial smooth muscle cells. Journal of Hypertension. 1987;5:739–744
  64. Brem AS, Bina RB, King T, et al. Bidirectional activity of 11 beta-hydroxysteroid dehydrogenase in vascular smooth muscle cells. Steroids. 1995;60:406–410
  65. Alzamora R, Michea L, Marusic ET. Role of 11beta-hydroxysteroid dehydrogenase in nongenomic aldosterone effects in human arteries. Hypertension. 2000;35:1099–1104
  66. Brem AS, Bina RB, Hill N, et al. Effects of licorice derivatives on vascular smooth muscle function. Life Sciences. 1997;60:207–214
  67. Souness GW, Brem AS, Morris DJ. 11 Beta-hydroxysteroid dehydrogenase antisense affects vascular contractile response and glucocorticoid metabolism. Steroids. 2002;67:195–201
  68. Muto S, Nemoto J, Ebata S, et al. Corticosterone and 11-dehydrocorticosterone stimulate Na,K-ATPase gene expression in vascular smooth muscle cells. Kidney International. 1998;54:492–508
  69. Whitworth JA, Schyvens CG, Zhang Y, et al. The nitric oxide system in glucocorticoid-induced hypertension. Journal of Hypertension. 2002;20:1035–1043
  70. Brem AS, Bina RB, King TC, et al. Localization of 2 11beta-OH steroid dehydrogenase isoforms in aortic endothelial cells. Hypertension. 1998;31:459–462
  71. Quaschning T, Ruschitzka F, Shaw S, et al. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension. 2001;37:801–805
  72. Hadoke PW, Christy C, Kotelevtsev YV, et al. Endothelial cell dysfunction in mice after transgenic knockout of type 2, but not type 1, 11beta-hydroxysteroid dehydrogenase. Circulation. 2001;104:2832–2837
  73. Kayes-Wandover KM, White PC. Steroidogenic enzyme gene expression in the human heart. The Journal of Clinical Endocrinology and Metabolism. 2000;85:2519–2525
  74. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. The New England Journal of Medicine. 1999;341:709–717
  75. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. The New England Journal of Medicine. 2003;348:1309–1321
  76. Funder JW. Is aldosterone bad for the heart?. Trends in Endocrinology and Metabolism. 2004;15:139–142
  77. Qin W, Rudolph AE, Bond BR, et al. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circulation Research. 2003;93:69–76
  78. Kotelevtsev Y, Holmes MC, Burchell A, et al. 11Beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress. Proceedings of the National Academy of Sciences of the U S A. 1997;94:14924–14929
  79. Gomez-Sanchez EP. Brain mineralocorticoid receptors: orchestrators of hypertension and end-organ disease. Current Opinion in Nephrology and Hypertension. 2004;13:191–196
  80. Gomez-Sanchez EP, Venkataraman MT, Thwaites D, et al. ICV infusion of corticosterone antagonizes ICV-aldosterone hypertension. The American Journal of Physiology. 1990;258:E649–E653
  81. Seckl JR. 11Beta-hydroxysteroid dehydrogenase in the brain: a novel regulator of glucocorticoid action?. Frontiers in Neuroendocrinology. 1997;18:49–99
  82. De Kloet ER, Van Acker SA, Sibug RM, et al. Brain mineralocorticoid receptors and centrally regulated functions. Kidney International. 2000;57:1329–1336
  83. Gomez-Sanchez EP, Gomez-Sanchez CE. Central hypertensinogenic effects of glycyrrhizic acid and carbenoxolone. The American Journal of Physiology. 1992;263:E1125–E1130
  84. Zhang ZH, Kang YM, Yu Y, et al. 11{Beta}-hydroxysteroid dehydrogenase type 2 activity in hypothalamic paraventricular nucleus modulates sympathetic excitation. Hypertension. 2006;48:127–133
  85. Geerling JC, Engeland WC, Kawata M, et al. Aldosterone target neurons in the nucleus tractus solitarius drive sodium appetite. The Journal of Neuroscience. 2006;26:411–417
  86. Cooney AS, Fitzsimons JT. Increased sodium appetite and thirst in rat induced by the ingredients of liquorice, glycyrrhizic acid and glycyrrhetinic acid. Regulatory Peptides. 1996;66:127–133
  87. Barker DJ, Osmond C, Golding J, et al. Growth in utero, blood pressure in childhood and adult life, and mortality from cardiovascular disease. British Medical Journal. 1989;298:564–567
  88. Law CM, Shiell AW. Is blood pressure inversely related to birth weight? The strength of evidence from a systematic review of the literature. Journal of Hypertension. 1996;14:935–941
  89. Alexander BT. Fetal programming of hypertension. American Journal of Physiology. Regulatory, Integrative and Comparative Physiology. 2006;290:R1–R10
  90. Seckl JR. Prenatal glucocorticoids and long-term programming. European Journal of Endocrinology. 2004;151(supplement 3):U49–U62
  91. Lindsay RS, Lindsay RM, Edwards CR, et al. Inhibition of 11-beta-hydroxysteroid dehydrogenase in pregnant rats and the programming of blood pressure in the offspring. Hypertension. 1996;27:1200–1204
  92. Welberg LA, Seckl JR, Holmes MC. Prenatal glucocorticoid programming of brain corticosteroid receptors and corticotrophin-releasing hormone: possible implications for behaviour. Neuroscience. 2001;104:71–79
  93. Ortiz LA, Quan A, Zarzar F, et al. Prenatal dexamethasone programs hypertension and renal injury in the rat. Hypertension. 2003;41:328–334
  94. Langley-Evans SC, Phillips GJ, Benediktsson R, et al. Protein intake in pregnancy, placental glucocorticoid metabolism and the programming of hypertension in the rat. Placenta. 1996;17:169–172
  95. Stewart PM, Rogerson FM, Mason JI. Type 2 11 beta-hydroxysteroid dehydrogenase messenger ribonucleic acid and activity in human placenta and fetal membranes: its relationship to birth weight and putative role in fetal adrenal steroidogenesis. The Journal of Clinical Endocrinology and Metabolism. 1995;80:885–890
  96. McTernan CL, Draper N, Nicholson H, et al. Reduced placental 11beta-hydroxysteroid dehydrogenase type 2 mRNA levels in human pregnancies complicated by intrauterine growth restriction: an analysis of possible mechanisms. The Journal of Clinical Endocrinology and Metabolism. 2001;86:4979–4983
  97. Dodic M, Moritz K, Koukoulas I, et al. Programmed hypertension: kidney, brain or both?. Trends in Endocrinology and Metabolism. 2002;13:403–408

PII: S1521-690X(06)00047-9

doi: 10.1016/j.beem.2006.07.001

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 20, Issue 3 , Pages 337-353 , September 2006

Article Tools

* Image Usage & Resolution